Eli Lilly and Company $LLY Stock Holdings Cut by Tompkins Financial Corp

Key Points

• Tompkins Financial Corp reduced its holdings in Eli Lilly and Company by 6.5%, leaving them with 30,927 shares valued at $24.1 million, making it their 10th largest investment.
• Eli Lilly recently reported earnings of $6.31 per share, surpassing expectations, and its quarterly revenue grew by 37.6% year-over-year to $15.56 billion.
• Insider transactions included Director Jamere Jackson and Gabrielle Sulzberger purchasing 200 and 117 shares respectively, with both trades indicating an increase in their ownership stake.

Tompkins Financial Corp decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 6.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 30,927 shares of the company's stock after selling 2,144 shares during the period. Eli Lilly and Company makes up approximately 2.2% of Tompkins Financial Corp's holdings, making the stock its 10th largest position. Tompkins Financial Corp's holdings in Eli Lilly and Company were worth $24,109,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. WestEnd Advisors LLC increased its stake in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company in the 1st quarter worth $27,000. Citizens National Bank Trust Department raised its stake in shares of Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in shares of Eli Lilly and Company in the 1st quarter valued at about $40,000. Finally, TD Capital Management LLC grew its position in shares of Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after buying an additional 31 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on LLY. Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. UBS Group reduced their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Wall Street Zen downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Finally, JPMorgan Chase & Co. cut their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $939.61.

Insider Activity

In other news, CEO David A. Ricks purchased 1,632 shares of the stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded down $9.41 on Friday, hitting $753.52. The company's stock had a trading volume of 7,319,147 shares, compared to its average volume of 3,181,974. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock's 50 day moving average is $738.37 and its 200-day moving average is $771.89. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $939.86. The company has a market capitalization of $713.18 billion, a PE ratio of 49.25, a PEG ratio of 1.06 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.